Teva's patent failure gives long-acting Copaxone generics free rein
admin 15th October 2018 Uncategorised 0Teva’s strategy for padding its Copaxone franchise even in the face of generic competition just took a major hit. The company lost its appeals court bid to defend the long-acting version of the MS drug—the very product Teva intended to take up slack as copycats steal share from the original.
More: Teva's patent failure gives long-acting Copaxone generics free rein
Source: fierce